All In Biotech

Drug Trial Radar · NCT06453265

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

A Double-Blind, Randomized, Crossover Study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users

Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jun 28, 2024

Primary completion

Nov 6, 2024

Study completion Nov 6, 2024

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
National Institutes of Health (NIH)
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users.

Conditions

  • Abuse, Drug

Interventions

  • Cebranopadol- 600 ugDrug

    Dose ascending cohorts \- Cebranopadol 600 ug single dose

  • Cebranopadol- 800ugDrug

    Dose ascending cohorts \- Cebraopadol 800 ug single dose

  • Cebranopadol- 1000ugDrug

    Dose ascending cohorts \- Cebranopadol 1000 ug single dose

  • Treatment A:Drug

    Cebranopadol, dose determined in Part A

  • Treatment BDrug

    Oxycodone HCl IR 40 mg

  • Treatment CDrug

    Placebo

  • QualificationDrug

    Oxycodone 40mg

  • QualificationDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Drug Liking VAS EmaxTime frame: 48 hrs of Tmax for each treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ohio Clinical Trials, Inc.

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.